Ali Behbahani, M.D., has been a member of our board of directors since April 2020. Dr. Behbahani joined New Enterprise Associates, Inc., a venture capital firm, in 2007 and is a Partner and Co-Head of Healthcare. Prior to joining New Enterprise Associates, Inc., Dr. Behbahani served as a consultant in business development at The Medicines Company, a pharmaceutical company, a Venture Associate at Morgan Stanley, a multinational investment bank and financial services company, and a Healthcare Investment Banking Analyst at Lehman Brothers, a global financial services firm, from 1998 to 2000. Dr. Behbahani serves as a member of the board of directors of SpyGlass Pharma, Inc., a publicly-traded biopharmaceutical company, since May 2019, Nkarta, Inc., a publicly-traded biotechnology company, since August 2015, Black Diamond Therapeutics, Inc., a publicly-traded biopharmaceutical company, since December 2018, CRISPR Therapeutics AG, a publicly-traded biotechnology company, since March 2015, Korro Bio, Inc., a publicly-traded biotechnology company, since August 2019, and Arcellx, Inc., a publicly-traded biotechnology company, since February 2015. Dr. Behbahani formerly served as a member of the board of directors of Adaptimmune Therapeutics plc, a publicly-traded biopharmaceutical company, from September 2014 to November 2025, CVRx, Inc., a publicly-traded medical device company, from July 2013 to September 2024, Nevro Corp., a publicly-traded global medical device company, from August 2014 to March 2019, Oyster Point Pharma, Inc., a privately-held biopharmaceutical company, from July 2017 to January 2023, Genocea Biosciences, Inc., a publicly-traded biopharmaceutical company, from February 2018 to May 2022, Minerva Surgical Inc., a privately-held biotechnology company, from May 2011 to January 2024, and Marker Therapeutics, Inc., a publicly-traded biopharmaceutical company, until 2017. Dr. Behbahani received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University. We believe that Dr. Behbahani is qualified to serve as a member of our board of directors because of his extensive corporate leadership experience and expertise in finance and investment management.